Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1993-5-21
|
pubmed:abstractText |
To study the hemodynamic and metabolic effects of chronic inhibition of endothelium-derived nitric oxide, we treated conscious rats with an oral solution of N omega-nitro-L-arginine (LNA), an inhibitor of nitric oxide production by endothelial cells. After 3 days of treatment with 2.74 mM LNA, rats had higher blood pressures (136 +/- 5 versus 113 +/- 3 mm Hg, p < 0.0005) than did the control animals. This effect was maintained through 7 days of treatment (142 +/- 6 versus 109 +/- 4 mm Hg, p < 0.0005) and in three animals for 35 days (167 +/- 7 mm Hg). The blood pressure rise was dose dependent. The hypertensive effect of oral LNA was not enhanced by the administration of 20 mg intraperitoneal LNA and was prevented by pretreatment with L-arginine, although L-arginine also caused a transient but significant increase in urinary sodium excretion. When LNA treatment was discontinued, blood pressure fell gradually, with an effective biological half-life of 4.2 days. Metabolic balance studies did not identify differences in sodium or potassium balance between treated and control animals. Plasma renin activity was lower in LNA-treated animals, and aldosterone concentrations tended to be lower. In contrast, atrial natriuretic factor levels and serum electrolyte concentrations were unchanged after 7 days of treatment with LNA. These data support the premise that endothelium-derived nitric oxide plays an important role in basal hemodynamic homeostasis. Oral administration of LNA may serve as a model of chronic nitric oxide-deficient hypertension and allow for the future study of endothelium dependence in hypertension.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0194-911X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
359-63
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8478045-Administration, Oral,
pubmed-meshheading:8478045-Animals,
pubmed-meshheading:8478045-Arginine,
pubmed-meshheading:8478045-Blood Pressure,
pubmed-meshheading:8478045-Heart Rate,
pubmed-meshheading:8478045-Male,
pubmed-meshheading:8478045-Nitric Oxide,
pubmed-meshheading:8478045-Nitroarginine,
pubmed-meshheading:8478045-Rats,
pubmed-meshheading:8478045-Rats, Sprague-Dawley,
pubmed-meshheading:8478045-omega-N-Methylarginine
|
pubmed:year |
1993
|
pubmed:articleTitle |
Sustained hypertension induced by orally administered nitro-L-arginine.
|
pubmed:affiliation |
Division of Endocrinology, University of Michigan, Ann Arbor 48109-0678.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|